ReviewFuture medicinal chemistry2012
miRNAs as potential therapeutic targets for age-related macular degeneration.
Review in Future medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Can MicroRNAs serve as reliable biomarkers and novel therapeutic targets in age-related macular degeneration? A systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- Next-generation sequencing reveals aqueous MicroRNA and piRNA signatures in age-related macular degeneration and polypoidal choroidal vasculopathy.Molecular and cellular biochemistry · 2026Article
- Extracellular Matrix (ECM) Aging in the Retina: The Role of Matrix Metalloproteinases (MMPs) in Bruch's Membrane Pathology and Age-Related Macular Degeneration (AMD).Biomolecules · 2025Review
- Review
- Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions.Investigative ophthalmology & visual science · 2023Review
- The Role of Dysregulated miRNAs in the Pathogenesis, Diagnosis and Treatment of Age-Related Macular Degeneration.International journal of molecular sciences · 2022Review
- Differential Circulating MicroRNA Expression in Age-Related Macular Degeneration.International journal of molecular sciences · 2021Article
- RNA therapeutics for retinal diseases.Expert opinion on biological therapy · 2021Review
- MicroRNAs in laser-induced choroidal neovascularization in mice and rats: their expression and potential therapeutic targets.Neural regeneration research · 2021Article
- The Role of Deregulated MicroRNAs in Age-Related Macular Degeneration Pathology.Translational vision science & technology · 2021Article
- Inhibition of microRNA-155 Protects Retinal Function Through Attenuation of Inflammation in Retinal Degeneration.Molecular neurobiology · 2021Article
- MicroRNA-27a Promotes Oxidative-Induced RPE Cell Death through Targeting FOXO1.BioMed research international · 2021Article
- Exosomal MiRNA Transfer between Retinal Microglia and RPE.International journal of molecular sciences · 2020Article
- Identification of Novel Serum MicroRNAs in Age-Related Macular Degeneration.Translational vision science & technology · 2020Article
- Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease.Frontiers in pharmacology · 2020Review
- Mutation-Independent Therapies for Retinal Diseases: Focus on Gene-Based Approaches.Frontiers in neuroscience · 2020Review
- miR302a and 122 are deregulated in small extracellular vesicles from ARPE-19 cells cultured with HScientific reports · 2019Article
- Article
- MicroRNA-124 Dysregulation is Associated With Retinal Inflammation and Photoreceptor Death in the Degenerating Retina.Investigative ophthalmology & visual science · 2018Article
- Extracellular vesicle-mediated long-range communication in stressed retinal pigment epithelial cell monolayers.Biochimica et biophysica acta. Molecular basis of disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Since their recent discovery, miRNAs have been shown to play critical roles in a variety of pathophysiological processes. Such processes include pathological angiogenesis, the oxidative stress response, immune response and inflammation, all of which have been shown to have important and interdependent roles in the pathogenesis and progression of age-related macular degeneration (AMD). Here we present a brief review of the pathological processes involved in AMD and review miRNAs and other noncoding RNAs involved in regulating these processes. Specifically, we discuss several candidate miRNAs that show promise as AMD therapeutic targets due to their direct involvement in choroidal neovascularization or retinal pigment epithelium atrophy. We discuss potential miRNA-based therapeutics and delivery methods for AMD and provide future directions for the field of miRNA research with respect to AMD. We believe the future of miRNAs in AMD therapy is promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.